Arcus Biosciences (RCUS) has jumped back onto investor screens after updated clinical data for its kidney cancer drug candidate casdatifan, a broad pipeline update, and full year 2025 earnings, all released in quick succession.

Those casdatifan data and the broader pipeline update arrived alongside full year results and fresh shelf and at the market filings. After an earlier stock jump around Q4 earnings, Arcus’ 1 day share price return of 0.45% decline and 7 day share price return of 7.64% decline sit against a 1 year total shareholder return of 134.96%. This suggests long term momentum has been strong even as shorter term share price performance has cooled.

If this kind of biotech volatility has your attention, it could be a good moment to widen your watchlist and check out 32 healthcare AI stocks as potential next ideas to research.

With Arcus trading at US$22.11, a value score of 4, an intrinsic value estimate pointing to a sizeable discount, and a large gap to analyst targets, is the market missing something here or already pricing in future growth?

Most Popular Narrative: 31.5% Undervalued

Against the last close of $22.11, the most followed narrative points to a fair value of $32.30, leaving a sizable valuation gap for investors to weigh.

Arcus Biosciences is prioritizing the launch of its late-stage development program for the HIF-2 alpha inhibitor, casdatifan, which has shown significant efficacy differentiation relative to existing market competitors. This could enhance future revenue through competitive advantage in the RCC market.

Curious what kind of revenue path and future margins sit behind that fair value, and how much weight is placed on casdatifan versus the rest of the pipeline? The narrative spells out a specific growth profile, earnings trajectory and valuation multiple that together need to line up for that $32.30 figure to hold.

Result: Fair Value of $32.30 (UNDERVALUED)

However, that 31.5% valuation gap leans heavily on successful regulatory outcomes and assumes competitors do not erode the projected opportunity for casdatifan and Arcus’ broader pipeline.

Another Angle On Valuation

Our DCF model presents a different perspective. On this view, Arcus at $22.11 is trading 83.9% below an estimated future cash flow value of $137.73, which is also flagged as undervalued. When two methods both point to a gap this wide, are expectations simply too optimistic, or is sentiment too cautious?

Next Steps

Given the mix of optimism and caution running through this story, it makes sense to move fast and test the numbers for yourself using 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Arcus has sharpened your focus, do not stop here. Use the Simply Wall St Screener to spot other opportunities that might fit your approach.

• Target resilient compounding potential with 64 resilient stocks with low risk scores that aim to keep risk in check while still leaving room for returns.
• Hunt for quality at a discount using 50 high quality undervalued stocks to see which companies our filters highlight as trading below their assessed worth.
• Spot lesser known opportunities by reviewing our screener containing 24 high quality undiscovered gems that combine solid fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.